Literature DB >> 15662534

[Refractory cutaneous necrotizing vasculitis. Successful sulfone therapy].

H Seybold1, M Simon, G Schuler, M Lüftl.   

Abstract

The clinical picture in vasculitis varies from few self-limiting symptoms to life-threatening illnesses affecting multiple organs. We describe the course of a woman patient who had had a severe cutaneous necrotizing vasculitis for more than 10 years. Various immunsuppressants, including cyclophosphamide, had failed to improve the clinical course, although adequate doses were given for a sufficient period. Treatment with DADPS (diaminodiphenylsulfone, dapsone), however, finally led to complete remission of the severe and chronic vasculitic ulcerations. Indications for DADPS treatment of inflammatory cutaneous diseases are discussed, and an overview of cutaneous vasculitis is provided.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 15662534     DOI: 10.1007/s00105-004-0889-y

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  13 in total

Review 1.  Novel therapies in vasculitis.

Authors:  C Thomas-Golbanov; S Sridharan
Journal:  Expert Opin Investig Drugs       Date:  2001-07       Impact factor: 6.206

2.  Erythema elevatum diutinum--evidence for disease-dependent leucocyte alterations and response to dapsone.

Authors:  J Grabbe; N Haas; A Möller; B M Henz
Journal:  Br J Dermatol       Date:  2000-08       Impact factor: 9.302

3.  The American College of Rheumatology 1990 criteria for the classification of vasculitis. Introduction.

Authors:  G G Hunder; W P Arend; D A Bloch; L H Calabrese; A S Fauci; J F Fries; R Y Leavitt; J T Lie; R W Lightfoot; A T Masi
Journal:  Arthritis Rheum       Date:  1990-08

4.  Pyoderma gangrenosum with rheumatoid arthritis and pulmonary aseptic abscess responding to treatment with dapsone.

Authors:  K Fukuhara; Y Urano; S Kimura; K Hori; S Arase
Journal:  Br J Dermatol       Date:  1998-09       Impact factor: 9.302

Review 5.  Nomenclature of systemic vasculitides. Proposal of an international consensus conference.

Authors:  J C Jennette; R J Falk; K Andrassy; P A Bacon; J Churg; W L Gross; E C Hagen; G S Hoffman; G G Hunder; C G Kallenberg
Journal:  Arthritis Rheum       Date:  1994-02

6.  Inhibition of neutrophil adherence to antibody by dapsone: a possible therapeutic mechanism of dapsone in the treatment of IgA dermatoses.

Authors:  V Thuong-Nguyen; D P Kadunce; J D Hendrix; W R Gammon; J J Zone
Journal:  J Invest Dermatol       Date:  1993-04       Impact factor: 8.551

Review 7.  Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years.

Authors:  A S Fauci; B F Haynes; P Katz; S M Wolff
Journal:  Ann Intern Med       Date:  1983-01       Impact factor: 25.391

8.  Dapsone in Behçet's disease: a double-blind, placebo-controlled, cross-over study.

Authors:  Khalifa E Sharquie; Rafid A Najim; Ahmed R Abu-Raghif
Journal:  J Dermatol       Date:  2002-05       Impact factor: 4.005

9.  Sulfone therapy in the treatment of leukocytoclastic vasculitis. Report of three cases.

Authors:  M F Fredenberg; F D Malkinson
Journal:  J Am Acad Dermatol       Date:  1987-04       Impact factor: 11.527

10.  On the efficacy of dapsone in granuloma faciale.

Authors:  P C van de Kerkhof
Journal:  Acta Derm Venereol       Date:  1994-01       Impact factor: 4.437

View more
  1 in total

Review 1.  Localized Forms of Vasculitis.

Authors:  Joana Martins-Martinho; Eduardo Dourado; Nikita Khmelinskii; Pablo Espinosa; Cristina Ponte
Journal:  Curr Rheumatol Rep       Date:  2021-07-01       Impact factor: 4.592

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.